Get access

Strong control over multiple endpoints: are we adding value to the assessment of medicines?

Authors


Correspondence to: Andrew Stone, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, UK.

E-mail: Andrew.stone@astrazeneca.com

No abstract is available for this article.

Get access to the full text of this article

Ancillary